Abstracts Archive - Page 844 of 2607 - ACR Meeting Abstracts

Abstract Number: 0114 • ACR Convergence 2020
Incidence of Follow-Up Dual-Energy X-Ray Absorptiometry Scanner Error: A Contributor to Precision Error
Kevin Lee¹, Karam Al Jumaily¹, Mu Lin², Kerry Siminoski³ and Carrie Ye⁴, ¹Internal Medicine, University of Alberta, Edmonton, AB, Canada, ²Alberta Health Services, Edmonton, AB, Canada, ³Radiology, University of Alberta, Edmonton, AB, Canada, ⁴Rheumatology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Osteoporosis is characterized by decreased bone tissue microarchitecture. This leads to reduced bone density and quality and is a significant contributor to morbidity, mortality,…
Abstract Number: 0115 • ACR Convergence 2020
Improving Osteoporosis Screening in Men at a Resident-run Primary Care Clinic: A Quality Improvement Project
Khiem Vu¹, Chima Ohadugha¹, Kevin Dao¹, Rabih Nayfe² and Andrew Mangano¹, ¹Grand Strand Medical Center, Myrtle Beach, SC, ²Carolina Health Specialists - Rheumatology, Myrtle Beach, SC
Background/Purpose: There are known indications for osteoporosis screening in women. However, osteoporosis also occurs in men and fragility fractures are linked to increased morbidity and…
Abstract Number: 0116 • ACR Convergence 2020
The in Vitro 3D Fracture Gap Model: A Tool for Preclinical Testing
Moritz Pfeiffenberger¹, Alexandra Damerau¹, Paula Hoff², Annemarie Lang¹, Frank Buttgereit³ and Timo Gaber¹, ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ²Endokrinologikum Berlin, Rheumatologie, Berlin, Germany, ³Charité University Medicine, Berlin, Germany
Background/Purpose: Approximately 10% of fractures lead to significant fracture healing disorders. Of note, especially immunosuppressed patients with ongoing inflammation show difficulties in the correct course…
Abstract Number: 0117 • ACR Convergence 2020
Development of an In Vitro Trabecular Human Bone Model to Recapitulate Features of Glucocorticoid-induced Osteoporosis
Annemarie Lang¹, Karoline Diesing¹, Alexandra Damerau¹, Moritz Pfeiffenberger¹, Timo Gaber¹ and Frank Buttgereit², ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ²Charité University Medicine, Berlin, Germany
Background/Purpose: The bone matrix consists of inorganic and organic components and a variety of specialized cells such as osteoblasts, osteocytes and osteoclasts. The bone-forming osteoblasts…
Abstract Number: 0118 • ACR Convergence 2020
Indicators of Effectiveness After 6 Years of Follow-up in a Fracture Liaison Service
Antonio Naranjo Hernandez¹, Amparo Molina², Cristina Sepúlveda², Francisco Rubiño³, Adrian Quevedo³ and Soledad Ojeda³, ¹Hospital Universitario Dr Negrin, Las Palmas, Canarias, Spain, ²Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas, Spain, ³Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas
Background/Purpose: Data on the effectiveness of FLS in the medium and long term are needed. The objetive of this study was to analyze the indicators of…
Abstract Number: 0119 • ACR Convergence 2020
Fracture Liaison Service at an Academic Center with an Open Health System: 30-month Outcomes
Donna Jose¹, Micah Yu², Karina Torralba³, Christina Downey⁴, Justin Dunn⁵ and Vinicius Cabido⁵, ¹Loma Linda University Medical Center, Ontario, CA, ²Loma Linda University Medical Center, Loma Linda, CA, ³Loma Linda University School of Medicine, Redlands, CA, ⁴Loma Linda University Medical Center, Redlands, CA, ⁵Loma Linda University Medical Center, Loma Linda
Background/Purpose: Osteoporosis causes significant morbidity, mortality and healthcare burden. There continues to be a care gap in osteoporosis recognition, treatment and prevention. Several healthcare systems…
Abstract Number: 0120 • ACR Convergence 2020
Risk of Fracture in Patients with Different Glucocorticoid Requiring Diseases
Giovanni Adami¹, Angelo Fassio², Alessandro Giollo², Luca Idolazzi², Ombretta Viapiana¹, Davide Gatti² and Maurizio Rossini², ¹University of Verona, Verona, Italy, ²Rheumatology Unit, University of Verona, Verona, Italy
Background/Purpose: The aim of the present work is to determine the fracture risk associated with glucocorticoids requiring diseasesMethods: We conducted a retrospective analysis of a nation-wide…
Abstract Number: 0121 • ACR Convergence 2020
Association of Low Bone Density with Need for Early Revision After Elective Joint Replacement for Osteoarthritis in Postmenopausal Women
Rashmi Dhital¹, P. Daniel Nicholas², Gregory Emkey³ and Anthony Donato², ¹Reading Hospital and Medical Center, West Reading, ²Reading Hospital and Medical Center, West Reading, PA, ³Reading Hospital and Medical Center, Reading, PA
Background/Purpose: Total joint replacement (TJR) is the standard surgical treatment for end-stage hip and knee osteoarthritis (OA). Patient optimization may limit the need for early…
Abstract Number: 0122 • ACR Convergence 2020
Osteoporosis Medication Utilization Patterns over Time in the ACR RISE Registry
Nitasha Khullar¹, Lang Chen², Jeffrey R Curtis³, Joshua Baker⁴, Huifeng Yun³, Andreas Reimold⁵ and Maria (Maio) Danila⁶, ¹University of Alabama Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX, ⁶University of Alabama at Birmingham (UAB), Birmingham, AL
Background/Purpose: Many effective medications are available for osteoporosis treatment. However how rheumatologists use these therapies is not well understood, particularly in patients with concomitant rheumatologic…
Abstract Number: 0123 • ACR Convergence 2020
Aromatase Inhibitor-Associated Bone Loss: Screening and Prevention
Matthew White¹ and Luke Barre², ¹Roger Williams Medical Center, Providence, RI, ²Hawthorn Medical Associates, Dartmouth, MA
Background/Purpose: Aromatase inhibitors (AI) are frequently used in hormone receptor-positive breast cancer, which encompasses nearly 75% of all breast cancers. By preventing peripheral estrogen production,…
Abstract Number: 0124 • ACR Convergence 2020
Appropriate Timing of Denosumab Dosing and Subsequent Therapy After Discontinuation: An Academic Medical Center Experience
Hugo Raposo¹, Daniel Lindstrom¹ and Jonathan Cheah², ¹University of Massachusetts Medical School, Worcester, MA, ²University of Massachusetts Medical School, Shrewsbury, MA
Background/Purpose: Denosumab, a monoclonal antibody that binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) is a popular choice for osteoporosis therapy. However,…
Abstract Number: 0125 • ACR Convergence 2020
A Resident-Led Interdisciplinary Quality Improvement Initiative to Increase Osteoporosis Screening in an Urban Clinic
Catherine Teskin¹ and Hiba Sayed², ¹Christiana Care, Wilmington, ²Christiana Care, wilmington, DE
Background/Purpose: Osteoporosis is a major cause of morbidity and mortality in the United States. The USPSTF recommends screening all women age 65 and older or…
Abstract Number: 0126 • ACR Convergence 2020
Immunophenotyping of Peripheral Blood Highlights an Association of Dysregulated Lymphocytes with Patients with Glucocorticoid-induced Osteonecrosis
Kaichi Kaneko¹, Hao Chen¹, Alexandra Krez², Steven Zeng¹, Peter Park¹, Ye-Ji Lee¹, Takayuki Fujii¹, Haemin Kim¹, Sehwan Mun¹, Seyeon Bae¹, Tania Pannellini³, Joseph Lane⁴, Derek Hansen⁴, Douglas Mintz⁵, Richard Bockman², Emily Stein⁶ and Kyung-Hyun Park-Min⁷, ¹Arthritis and Tissue Degeneration Program, David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ²Endocrine Service, Hospital for special surgery, New York, NY, ³Pathology and Precision Medicine Laboratory, Hospital for special surgery, New York, NY, ⁴Orthopedic surgery, Hospital for special surgery, Department of Medicine, Weill Cornell Medical College, New York, NY, ⁵Radiology, Hospital for special surgery, Department of Medicine, Weill Cornell Medical College, New York, NY, ⁶Endocrine Service, Hospital for special surgery, Department of Medicine, Weill Cornell Medical College, New York, NY, ⁷Arthritis and Tissue Degeneration Program, David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, Department of Medicine, Weill Cornell Medical College, New York, NY
Background/Purpose: Avascular necrosis (AVN) is a musculoskeletal condition that can result in significant pain and compromised quality of life. The diverse etiologies of AVN have…
Abstract Number: 0127 • ACR Convergence 2020
Biochemical Algorithm to Identify Individuals with ALPL Variants Between Subjects with Persistent Hypophosphatasaemia
Carolina Tornero¹, Victoria Navarro-Compán², Jair Antonio Tenorio³, Sara Garcia-Carazo⁴, Antonio Buño⁵, Irene Monjo¹, Chamaida Plasencia⁶, José Manuel Iturzaeta⁵, Pablo Lapunzina⁷, Karen Heath⁷, Alejandro Balsa⁶ and Pilar Aguado⁸, ¹Rheumatology, La Paz University Hospital- IdiPAZ, Madrid, Spain, ²Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ³Institute of Medical and Molecular Genetics (INGEMM), La Paz University Hospital-IdiPAZ, Madrid, Madrid, Spain, ⁴Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Melilla, Spain, ⁵Department of Clinical Biochemistry, La Paz University Hospital, Madrid, Madrid, Spain, ⁶Rheumatology, La Paz University Hospital-IdiPAZ, madrid, Spain, ⁷Institute of Medical and Molecular Genetics (INGEMM), La Paz University Hospital, IdiPAZ, Madrid, Madrid, Spain, ⁸Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Madrid, Spain
Background/Purpose: Studies show a long diagnostic delay in Hypophosphatasia (HPP) and the accessibility for the genetic testing is not always possible. Our previous cross-sectional study…
Abstract Number: 0128 • ACR Convergence 2020
Short-Term Monitoring of Denosumab Effect in Breast Cancer Patients Receiving Aromatase Inhibitors Using Radiofrequency Echographic Multi-Spectrometry (REMS) Technology on Femoral Neck
Rosachiara Forcignanò¹, Fiorella Anna Lombardi², Mariangela Ciccarese³, Eugenio Quarta⁴, Antonella Grimaldi⁵, Laura Quarta⁵, Delia Ciardo², Ernesto Casciaro², Paola Pisani², Francesco Conversano², Maurizio Muratore⁵ and Sergio Casciaro², ¹O.U. of Oncology, “Sacro Cuore di Gesù” Hospital, Gallipoli, Lecce, Italy, Gallipoli, Italy, ²National Research Council, Institute of Clinical Physiology, Lecce, Italy, Lecce, Italy, ³O.U. of Oncology, “Vito Fazzi” Hospital, ASL-LE, Lecce, Italy, Lecce, Italy, ⁴O.U. of Rheumatology, "Galateo" Hospital, ASL-LE, San Cesario di Lecce, Lecce, Italy, San Cesario di Lecce, Italy, ⁵O.U. of Rheumatology, “Galateo” Hospital, San Cesario di Lecce ASL-LE, Lecce, Italy, San Cesario di Lecce, Italy
Background/Purpose: The aim of the study was to carry out a short-term monitoring of the effect of aromatase inhibitors (AI) and Denosumab on bone health…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].